<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880618</url>
  </required_header>
  <id_info>
    <org_study_id>360049-001</org_study_id>
    <nct_id>NCT02880618</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction</brief_title>
  <acronym>HFrEF</acronym>
  <official_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM
      NEO System in the commercial setting in subjects recently implanted under the CE-Marked
      indication for heart failure with reduced ejection fraction (HFrEF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Change in New York Heart Association Functional Classification at 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Six Minute Hall Walk from Baseline to 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Mass Index Change from Baseline to 6 Months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Biomarkers from Baseline to 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>e.g. NT-pro BNP, eGFR, Troponin HsT, Cystatin C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalizations over Follow-Up</measure>
    <time_frame>12 months post-implant</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Barostim Neo™ System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects can be included in the Heart Failure with Reduced Ejection Fraction Registry if
        they were implanted in the past 30 days and meet the CE-Mark approved indications, and are
        not contraindicated, for the BAROSTIM NEO System in the treatment of heart failure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has signed an EC approved informed consent form

          -  Has been treated with the appropriate heart failure guideline directed therapy

          -  Has been implanted with the BAROSTIM NEO System in the past 30 days

          -  NYHA III and,

          -  LVEF ≤ 35%

        Exclusion Criteria:

          -  Bilateral carotid bifurcations located above the level of the mandible

          -  Baroreflex failure or autonomic neuropathy

          -  Uncontrolled, symptomatic cardiac bradyarrhythmias

          -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation
             to be greater than 50%

          -  Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Müller-Ehmsen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asklepios Klinik Altona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CVRx Vice President of Clinical Research</last_name>
    <phone>763-416-2876</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anika Struve</last_name>
      <phone>+49 431 500 22915</phone>
      <email>anika.struve@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Hendrik Bonnemeier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Dietrich</last_name>
      <phone>+49 (341) 97 12 408</phone>
      <email>jenny.dietrich@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Janine Starke</last_name>
      <phone>+49 (341) 97 12 443f</phone>
      <email>janine.starke@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Neef</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital and MVS Maria-Hilf Stadtlohn GmbH</name>
      <address>
        <city>Stadtlohn</city>
        <zip>489703</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Fitz</last_name>
      <phone>02563-912-203</phone>
      <email>b.fitz@kmh-stadtlohn.de</email>
    </contact>
    <investigator>
      <last_name>Alessandro Cuneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Landkreis Tuttlingen</name>
      <address>
        <city>Tuttlingen</city>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weber Ida</last_name>
      <phone>07461 97 1415</phone>
      <email>i.weber@klinikum-tut.de</email>
    </contact>
    <investigator>
      <last_name>Michael Kotzerke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015 Jun;3(6):487-96. doi: 10.1016/j.jchf.2015.02.006.</citation>
    <PMID>25982108</PMID>
  </reference>
  <reference>
    <citation>Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct;17(10):1066-74. doi: 10.1002/ejhf.299.</citation>
    <PMID>26011593</PMID>
  </reference>
  <reference>
    <citation>Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014 Sep;16(9):977-83. doi: 10.1002/ejhf.138. Epub 2014 Jul 28.</citation>
    <PMID>25067799</PMID>
  </reference>
  <reference>
    <citation>Gronda E, Seravalle G, Trevano FQ, Costantino G, Casini A, Alsheraei A, Lovett EG, Vanoli E, Mancia G, Grassi G. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction. J Hypertens. 2015 Aug;33(8):1704-8. doi: 10.1097/HJH.0000000000000603.</citation>
    <PMID>26132760</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 21, 2017</lastchanged_date>
  <firstreceived_date>August 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Reduced ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
